Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial

Giovannella Palmieri, Carlo Buonerba, Margaret Ottaviano, Piera Federico, Filomena Calabrese, Claudia Von Arx, Ana Paula De Maio, Mirella Marino, Maurizio Lalle, Liliana Montella, Carmela Merola, Michele Milella, Marina Bergaglio, Giuseppe Di Lorenzo, Vincenzo Damiano

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs). Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks). Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73%) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5). Conclusion: Capecitabine and gemcitabine is highly active in TETs.

Original languageEnglish
Pages (from-to)2141-2147
Number of pages7
JournalFuture Oncology
Volume10
Issue number14
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

gemcitabine
Thymoma
Capecitabine
Thymic epithelial tumor
Neutropenia
Disease-Free Survival

Keywords

  • capecitabine
  • gemcitabine
  • thymic epithelial tumors
  • thymomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Palmieri, G., Buonerba, C., Ottaviano, M., Federico, P., Calabrese, F., Von Arx, C., ... Damiano, V. (2014). Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial. Future Oncology, 10(14), 2141-2147. https://doi.org/10.2217/fon.14.144

Capecitabine plus gemcitabine in thymic epithelial tumors : Final analysis of a Phase II trial. / Palmieri, Giovannella; Buonerba, Carlo; Ottaviano, Margaret; Federico, Piera; Calabrese, Filomena; Von Arx, Claudia; De Maio, Ana Paula; Marino, Mirella; Lalle, Maurizio; Montella, Liliana; Merola, Carmela; Milella, Michele; Bergaglio, Marina; Di Lorenzo, Giuseppe; Damiano, Vincenzo.

In: Future Oncology, Vol. 10, No. 14, 01.11.2014, p. 2141-2147.

Research output: Contribution to journalArticle

Palmieri, G, Buonerba, C, Ottaviano, M, Federico, P, Calabrese, F, Von Arx, C, De Maio, AP, Marino, M, Lalle, M, Montella, L, Merola, C, Milella, M, Bergaglio, M, Di Lorenzo, G & Damiano, V 2014, 'Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial', Future Oncology, vol. 10, no. 14, pp. 2141-2147. https://doi.org/10.2217/fon.14.144
Palmieri G, Buonerba C, Ottaviano M, Federico P, Calabrese F, Von Arx C et al. Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial. Future Oncology. 2014 Nov 1;10(14):2141-2147. https://doi.org/10.2217/fon.14.144
Palmieri, Giovannella ; Buonerba, Carlo ; Ottaviano, Margaret ; Federico, Piera ; Calabrese, Filomena ; Von Arx, Claudia ; De Maio, Ana Paula ; Marino, Mirella ; Lalle, Maurizio ; Montella, Liliana ; Merola, Carmela ; Milella, Michele ; Bergaglio, Marina ; Di Lorenzo, Giuseppe ; Damiano, Vincenzo. / Capecitabine plus gemcitabine in thymic epithelial tumors : Final analysis of a Phase II trial. In: Future Oncology. 2014 ; Vol. 10, No. 14. pp. 2141-2147.
@article{35531ae7ee9d4c8e9f0e99b81facbe37,
title = "Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a Phase II trial",
abstract = "Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs). Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks). Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73{\%}) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5). Conclusion: Capecitabine and gemcitabine is highly active in TETs.",
keywords = "capecitabine, gemcitabine, thymic epithelial tumors, thymomas",
author = "Giovannella Palmieri and Carlo Buonerba and Margaret Ottaviano and Piera Federico and Filomena Calabrese and {Von Arx}, Claudia and {De Maio}, {Ana Paula} and Mirella Marino and Maurizio Lalle and Liliana Montella and Carmela Merola and Michele Milella and Marina Bergaglio and {Di Lorenzo}, Giuseppe and Vincenzo Damiano",
year = "2014",
month = "11",
day = "1",
doi = "10.2217/fon.14.144",
language = "English",
volume = "10",
pages = "2141--2147",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Capecitabine plus gemcitabine in thymic epithelial tumors

T2 - Final analysis of a Phase II trial

AU - Palmieri, Giovannella

AU - Buonerba, Carlo

AU - Ottaviano, Margaret

AU - Federico, Piera

AU - Calabrese, Filomena

AU - Von Arx, Claudia

AU - De Maio, Ana Paula

AU - Marino, Mirella

AU - Lalle, Maurizio

AU - Montella, Liliana

AU - Merola, Carmela

AU - Milella, Michele

AU - Bergaglio, Marina

AU - Di Lorenzo, Giuseppe

AU - Damiano, Vincenzo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs). Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks). Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73%) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5). Conclusion: Capecitabine and gemcitabine is highly active in TETs.

AB - Background: A multi-institutional Phase II trial was initiated in 2005 to test the combination gemcitabine and capecitabine in patients with thymic epithelial malignancies (TETs). Patients & methods: Patients with histologic confirmation of TET diagnosis by central review who had received >1 systemic chemotherapy treatment were included. Patients received oral capecitabine (650 mg/mq twice daily on days 1-14) and intravenous gemcitabine (1000 mg/mq on days 1 and 8 every 3 weeks). Results: Of the 30 patients included (18 men, 12 women; median age: 57 years, range: 48-61 years), the majority (73%) had thymoma, and the remaining thymic carcinoma. Eight patients developed grade 3-4 neutropenia. A total of 12 patients had a response. Median progression-free survival was 11 months (range: 6.5-16.5). Conclusion: Capecitabine and gemcitabine is highly active in TETs.

KW - capecitabine

KW - gemcitabine

KW - thymic epithelial tumors

KW - thymomas

UR - http://www.scopus.com/inward/record.url?scp=84916598112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916598112&partnerID=8YFLogxK

U2 - 10.2217/fon.14.144

DO - 10.2217/fon.14.144

M3 - Article

C2 - 25471029

AN - SCOPUS:84916598112

VL - 10

SP - 2141

EP - 2147

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -